In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hospital products company Cadence nets $57.8mm with IPO

Executive Summary

Cadence Pharmaceuticals (in-licenses treatments to develop for the hospital market) netted $57.8mm (including the overallotment) with its initial public offering, selling 6.9mm common shares for $9 apiece. Earlier it had hoped to raise up to $78mm from 6mm common shares at $11-13 apiece.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies